Keros Therapeutics Eyes 2027 DMD Data as Rinvatercept Takes Center StageMarketBeat · 2 days ago
Analyzing Upstream Bio (NASDAQ:UPB) and Keros Therapeutics (NASDAQ:KROS)Defense World · Oct 5, 2026
KROS Begins Dosing in Phase II Study With Rinvatercept in DMDZacks Investment Research · Sep 29, 2026
Keros Therapeutics to Receive Additional Development Milestone Payment from Partner TakedaGlobeNewsWire · Sep 29, 2026
Keros Therapeutics Announces the First Patient Dosing in the Phase 2 Clinical Trial Evaluating Rinvatercept in DMDGlobeNewsWire · Sep 28, 2026
Keros Therapeutics Announces $5 Million Share Repurchase AuthorizationGlobeNewsWire · Sep 8, 2026Keros Therapeutics, Inc., a biopharmaceutical entity in the clinical development phase, is focused on pioneering and commercializing innovative therapies for individuals afflicted by hematological and musculoskeletal conditions that currently lack adequate treatment options. Its flagship protein therapeutic, KER-050, is being advanced to address diminished blood cell counts (cytopenias), specifically anemia and thrombocytopenia, in patients diagnosed with myelodysplastic syndromes and myelofibrosis. Furthermore, the company is progressing KER-047, a small molecule designed to combat anemia, which is presently undergoing Phase 1 clinical evaluation.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 3, 2026 | -$1.34 | -$1.45 | Miss |
| May 14, 2026 | -$0.92 | -$1.21 | Miss |
| Mar 4, 2026 | -$0.49 | -$0.86 | Miss |
| Nov 5, 2025 | -$1.11 | -$0.18 | Beat |
| Aug 6, 2025 | -$1.14 | -$0.76 | Beat |
| May 6, 2025 | -$0.01 | $3.62 | Beat |